Loading...
•
Dec 31, 2024
Embecta Q1 2025 Earnings Report
Embecta reported solid performance driven by restructuring and brand transition plans.
Key Takeaways
Embecta Corp. reported a decrease in revenue by 5.6% to $261.9 million for the first quarter of fiscal year 2025. The company is progressing with its restructuring plan and brand transition, while also updating its financial guidance to reflect changes in foreign exchange assumptions and raising expectations for certain financial metrics.
Revenues decreased by 5.6% to $261.9 million.
Gross profit was $157.1 million with a margin of 60.0%.
Operating income was $28.7 million with a margin of 11.0%.
Net income was $0.0 million, with earnings per diluted share of $0.00.
Embecta
Embecta
Embecta Revenue by Segment
Embecta Revenue by Geographic Location
Revenue by Segment
Pen Needles Revenue
CapyFin.comSyringes Revenue
CapyFin.comSafety Revenue
CapyFin.comOther Revenue
CapyFin.comContract Manufacturing Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For fiscal year 2025, the company expects revenues between $1,075 million and $1,092 million and adjusted earnings per diluted share between $2.70 and $2.90.
Positive Outlook
- Adjusted Gross Margin: 63.25% - 64.25%
- Adjusted Operating Margin: 29.50% - 30.50%
- Adjusted Earnings per Diluted Share: $2.70 - $2.90
- Adjusted EBITDA Margin: 36.00% - 37.00%
Challenges Ahead
- Reported Revenues: $1,075 - $1,092 million (previous: $1,093 - $1,110 million)
- Reported Revenue Growth: (4.3)% - (2.8)% (previous: (2.7)% - (1.2)%)
- Impact of F/X: (2.2)% (previous: (0.6)%)
- Adjusted Constant Currency Revenue Growth (%): (2.5)% - (1.0)%